VisMederi is pleased to announce the establishment of VisMederi America, a new company based in Cleveland that marks a strategic milestone in the Group’s expansion into the United States. The new entity aims to strengthen VisMederi’s international presence, consolidate scientific partnerships and broaden collaboration opportunities in pre-clinical testing and vaccine research.
VisMederi’s founder, Emanuele Montomoli, has appointed Jennifer Price and Brian Price as Directors of the new company, bringing with them extensive expertise in biomedical research and the management of international scientific programs.
Supporting the connection between the Italian and U.S. operations, Elisa Mennitto and Alessandro Manenti will play a key role as the scientific and operational bridge between the two locations, ensuring continuity and a unified strategic direction.
VisMederi America brings together scientific excellence, operational experience and strategic development capability, with the goal of becoming a key player in pre-clinical testing — including Influenza, RSV, hMPV and SARS-CoV-2 — as well as a reliable partner for institutions, research centers and industry stakeholders.
A central aim of the new company is to enhance the Group’s ability to participate in U.S. public funding programs, thereby increasing opportunities for growth and innovation across its research activities.
The launch of VisMederi America represents an essential step in the Group’s global strategy.
Further updates will follow as new initiatives and development milestones are reached.
